Must Reads
Read every Must Reads article with Premium. Try 1 month for only $4.95* ยป
5 Mid-Cap Stocks Poised For Falling Rates
The government shutdown has created a significant data void, leaving investors and policymakers without timely economic reports, contributing to marke...
The Correction Is Just Getting Started
Markets are due for a near-term correction due to overextended technicals, exuberant valuations, and a more hawkish Federal Reserve. Despite short-ter...
Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026
Syndax Pharmaceuticals, Inc. remains a Buy, with Revuforj and Niktimvo launches accelerating and a strong clinical and commercial trajectory into 2026...
Accenture's 40% Selloff: A Rare Opportunity
Accenture plc appears undervalued after a 40% stock decline, now trading at just 14x free cash flow. Recent results show modest revenue growth and str...
The 'Smart Money' Is Increasingly Abandoning This Rally
Equities continue to trade near all-time highs even as the government shutdown continues and the jobs markets have clearly started to falter recently....
